ReviewSkeletal radiology2025
Ultrasonography in the assessment of calcium pyrophosphate deposition disease.
Review in Skeletal radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium pyrophosphate deposition (CPPD) disease is an arthropathy with increasing prevalence in the aging population that is associated with significant musculoskeletal morbidity. Although synovial fluid analysis (SFA) has been considered the gold standard for diagnosis, imaging is gaining an increasing role in the diagnosis and assessment of CPPD disease. Ultrasound (US) has proven to be useful in identifying calcium crystals while simultaneously assessing the surrounding inflammatory and structural damage consequent to calcific tissue deposition. Point-of-care ultrasound has the additional benefit of focusing the US evaluation to targeted symptomatic structures at the bedside, as well as allowing the sonographer to additionally scan joints frequently affected in CPPD disease to enhance the diagnostic utility of US. Furthermore, diagnostic and therapeutic procedures under US guidance can increase the yield of a diagnostic aspiration in CPPD disease and provide a therapeutic role in facilitating accurate delivery of medication in difficult to reach structures. Understanding the utility and limitations of US is essential to optimize the benefits of this imaging modality in the evaluation of CPPD disease.
Indexed as
Identifiers
39918638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.